Show simple item record

dc.contributor.authorPerea-Flórez, F.
dc.contributor.authorJavier-Murillo, N.
dc.contributor.authorLapeyre-Rivera, A.
dc.contributor.authorGamonal, B.
dc.contributor.authorCabanillas-Lazo, M.
dc.contributor.authorVelásquez-Rimachi, V.
dc.contributor.authorAlva-Diaz, C.
dc.date.accessioned2025-10-31T18:45:09Z
dc.date.available2025-10-31T18:45:09Z
dc.date.issued2023
dc.identifier.urihttps://hdl.handle.net/20.500.12805/6167
dc.description.abstractIntroduction: There are multiple reports of neuropsychiatric disorders (NDs) such as stress, depression, post-traumatic stress disorder (PTSD), or anxiety, in patients who have survived the acute phase of COVID-19, being even more frequent in people who were hospitalized with moderate or severe disease. South America (SA) was one of the most affected continents during this time due to its health, social, political and economic context. We aimed to determine the prevalence and incidence of NDs in patients following hospitalization for COVID-19 in SA. Materials and methods: We searched in PubMed, Embase, Scopus, Web of Science, LILACS, SciELO, and Google Scholar databases up to October 2022. We performed proportion meta-analysis with a random-effect model and Freeman-Tukey Double Arcsine transformation using the STATA 16.1 program. Finally, we evaluated heterogeneity by subgroup analysis and certainty of evidence with the GRADE approach. Results: We included eight studies from four countries. We only pooled six studies with prevalence measures. The estimated prevalence of all NDs was 31.48% (two-studies, 95%CI: 25.82–37.43). Depression, anxiety, insomnia, PTSD, and memory alterations had a pooled prevalence of 16.23% (three-studies, 95%CI: 7.18–27.93, I2: 94.22), 18.72% (three-studies, 95%CI: 11.65–26.97, I2: 87.56), 43.07% (three-studies, 95%CI: 32.77–53.37, I2: 92.61), 31.78% (three-studies, 95%CI: 14.33–52.40, I2: 97.96), and 38.24% (two-studies, 95%CI: 35.5–40.97), respectively. The evidence included was deemed as moderate to high certainty. Conclusion: We suggest that NDs should be prioritized in research and care in South America with public policies that can support their identification and prompt management to improve the quality of life of patients. More studies are needed to adequately study the prevalence of NDs in South America, their associated factors, and evaluate the causes of heterogeneity. Systematic review registration: https://doi.org/10.6084/m9.figshare.21901041.v1.en_US
dc.formatapplication/pdf
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofurn:issn:1664-0640
dc.rightshttps://purl.org/coar/access_right/c_abf2
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subjectCOVID-19, Its Impact, and Vaccinationen_US
dc.subjectLong COVID: Symptoms, Risks, and Rehabilitation Insightsen_US
dc.titlePrevalence and incidence of neuropsychiatric disorders in post hospitalized COVID-19 patients in South America: a systematic review and meta-analysisen_US
dc.typehttps://purl.org/coar/resource_type/c_dcae04bc
dc.identifier.doihttps://doi.org/10.3389/fpsyt.2023.1163989
dc.subject.ocdehttps://purl.org/pe-repo/ocde/ford#3.02.24
dc.type.otherReview
dc.identifier.journalFrontiers in Psychiatry
dc.type.versionhttps://purl.org/coar/version/c_970fb48d4fbd8a85


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://purl.org/coar/access_right/c_abf2
Except where otherwise noted, this item's license is described as https://purl.org/coar/access_right/c_abf2